MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1391-1396

  Zhou, Yong Ming ^a   Liu, Juan ^a   Sun, Wei ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gefitinib resistance; Met; miR 130a; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MET PROTEIN, HUMAN; MICRORNA; MIRN130 MICRORNA, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84896884571     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1391     Document Type: Article

References (30)

1. Acunzo M, Visone R, Romano G, et al (2012). miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene, 31, 634-42.
2. Belalcazar A, Azana D, Perez CA, et al (2012). Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther, 12, 519-28.
3. Boll K, Reiche K, Kasack K, et al (2013). MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene, 32, 277-85.
4. Burris HA, 3rd (2009). Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene, 28 Suppl 1, S4-13.
5. Chen Y, Gorski DH (2008). Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 111, 1217-26.
6. Dimitroulis J, Stathopoulos GP (2005). Evolution of non-small cell lung cancer chemotherapy (Review). Oncol Rep, 13, 923-30.
7. Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43.
8. Farazi TA, Spitzer JI, Morozov P, et al (2011). miRNAs in human cancer. J Pathol, 223, 102-15.
9. Garofalo M, Romano G, Di Leva G, et al (2012). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med, 18, 74-82.
10. Gazdar AF (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28 Suppl 1, S24-31.
11. Guo A, Villen J, Kornhauser J, et al (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A, 105, 692-7.
12. Kong YW, Ferland-McCollough D, Jackson TJ, et al (2012). microRNAs in cancer management. Lancet Oncol, 13, e249-58.
13. Kosaka T, Yatabe Y, Endoh H, et al (2006). Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res, 12, 5764-9.
14. Li H, Schmid-Bindert G, Wang D, et al (2011). Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci, 56, 275-84.
15. Luo W, Huang B, Li Z, et al (2013). MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One, 8, e64759.
16. Matoulkova E, Michalova E, Vojtesek B, et al (2012). The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol, 9, 563-76.
17. Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.
18. Mujahid S, Nielsen HC, Volpe MV (2013). MiR-221 and miR-130a regulate lung airway and vascular development. PLoS One, 8, e55911.
19. Oxnard GR, Miller VA (2010). Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park), 24, 392-9.
20. Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
21. Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, e73.
22. Ramachandran PV, Ignacimuthu S (2012). RNA Interference as a Plausible Anticancer Therapeutic Tool. Asian Pac J Cancer P, 13, 2445-52.
23. Sandberg R, Neilson JR, Sarma A, et al (2008). Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science, 320, 1643-7.
24. Sekido Y (2010). Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci, 101, 1-6.
25. Sequist LV, Martins RG, Spigel D, et al (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol, 26, 2442-9.
26. Suda K, Murakami I, Katayama T, et al (2010). Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res, 16, 5489-98.
27. Xu N, Shen C, Luo Y, et al (2012). Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun, 425, 468-72.
28. Yang F, Miao L, Mei Y, et al (2013). Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell Signal, 25, 1476-85.
29. Yang L, Li N, Wang H, et al (2012). Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep, 28, 592-600.
30. Zhang W, Mendoza MC, Pei X, et al (2012). Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem, 287, 11850-8.